Exact Sciences Corp SEC Filings

Director sale under 10b5-1 plan: A director of Exact Sciences Corp. (EXAS) sold 2,000 shares of common stock on 10/09/2025 at a price of $60 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the transaction the reporting person beneficially owned 57,962 shares. The sale was reported on a Form 4 executed by an attorney-in-fact. This filing discloses a single routine disposition by an insider using a pre-established plan and does not include other derivative or non-derivative transactions.

Exact Sciences (EXAS) reported a proposed sale of 1,500 common shares by an insider through Fidelity Brokerage Services with an aggregate market value of $90,000. The shares represent a small fraction of the company's outstanding common stock of 189,319,110 shares. The filer acquired these shares on 02/23/2022 through restricted stock vesting and the transaction is classified as compensation. The planned sale date is 10/09/2025 on NASDAQ. No other sales by the filer in the past three months were reported, and the filer certifies they are not aware of undisclosed material adverse information at the time of the notice.

Exact Sciences (EXAS) filing a Form 144 notifies a proposed sale of 2,000 common shares held by an insider through Fidelity Brokerage Services LLC with an aggregate market value of $120,000.00. The shares represent part of outstanding common stock of 189,319,110 shares and the planned approximate sale date is 10/09/2025 on NASDAQ. The filer reports the shares were acquired on 03/17/2022 via a stock option exercise and paid in cash.

The filing also discloses a sale of 1,485 shares on 08/13/2025 that generated gross proceeds of $62,399.70. The notice includes the standard representation that the seller does not possess undisclosed material adverse information and references Rule 10b5-1 timing language if applicable.

FMR LLC and Abigail P. Johnson report shared beneficial ownership of 18,588,183.06 shares of Exact Sciences Corp common stock, representing 9.8% of the class. FMR LLC is shown with 17,584,537.69 shares of sole voting power and 18,588,183.06 shares of sole dispositive power. The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. An exhibit is referenced for a related 13d-1(k) agreement.

James Edward Doyle, a director of Exact Sciences Corporation (EXAS), reported a sale of company common stock. The Form 4 shows a disposition of 1,485 shares on 08/13/2025 at a reported price of $42.02 per share under a Rule 10b5-1 trading plan established on 03/09/2025. After the sale, the filing reports 59,962 shares beneficially owned by Mr. Doyle. The Form 4 was signed via power of attorney on 08/14/2025.

Exact Sciences (EXAS) submitted a Form 144 notifying a proposed sale of 1,485 shares of common stock through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI 02917) with an aggregate market value of $62,399.70. The securities were acquired on 06/12/2025 by restricted stock vesting and payment is listed as compensation. The approximate date of sale is reported as 08/13/2025, and the filing states there were no securities sold during the past three months by the person for whose account the sale is proposed. The filing also discloses total shares outstanding of 189,319,110 and includes the standard representation that the filer does not know of any undisclosed material adverse information.